<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="os70150" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Orthop Surg</journal-id><journal-id journal-id-type="iso-abbrev">Orthop Surg</journal-id><journal-id journal-id-type="pmc-domain-id">3643</journal-id><journal-id journal-id-type="pmc-domain">orthopsurg</journal-id><journal-id journal-id-type="publisher-id">OS</journal-id><journal-title-group><journal-title>Orthopaedic Surgery</journal-title></journal-title-group><issn pub-type="ppub">1757-7853</issn><issn pub-type="epub">1757-7861</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12497545</article-id><article-id pub-id-type="pmcid-ver">PMC12497545.1</article-id><article-id pub-id-type="pmcaid">12497545</article-id><article-id pub-id-type="pmcaiid">12497545</article-id><article-id pub-id-type="pmid">40852892</article-id><article-id pub-id-type="doi">10.1111/os.70150</article-id><article-id pub-id-type="publisher-id">OS70150</article-id><article-id pub-id-type="other">OS-2025-05-0542</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Targeting Ferroptosis With Ginsenoside Rg3 Alleviates Intervertebral Disc Degeneration</article-title></title-group><contrib-group><contrib id="os70150-cr-0001" contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="W">Weiran</given-names></name><xref rid="os70150-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="os70150-cr-0002" contrib-type="author" corresp="yes"><name name-style="western"><surname>Geng</surname><given-names initials="F">Fei</given-names></name><xref rid="os70150-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>gengfei@ncst.edu.cn</email></address></contrib><contrib id="os70150-cr-0003" contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="K">Kaihui</given-names></name><xref rid="os70150-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="os70150-cr-0004" contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yinhuan</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-7274-6951</contrib-id><xref rid="os70150-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>642182440@qq.com</email></address></contrib></contrib-group><aff id="os70150-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">School of Basic Medicine Sciences</named-content>
<institution>North China University of Science and Technology</institution>
<city>Tangshan</city>
<country country="CN">China</country>
</aff><aff id="os70150-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Minimally Invasive Spine Surgery</named-content>
<institution>Tianjin Hospital, Tianjin University</institution>
<city>Tianjin</city>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Fei Geng (<email>gengfei@ncst.edu.cn</email>)<break/>
Yinhuan Wang (<email>642182440@qq.com</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>17</volume><issue seq="190">10</issue><issue-id pub-id-type="pmc-issue-id">498355</issue-id><issue-id pub-id-type="doi">10.1111/os.v17.10</issue-id><fpage>2960</fpage><lpage>2972</lpage><history><date date-type="rev-recd"><day>22</day><month>7</month><year>2025</year></date><date date-type="received"><day>07</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>29</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-07 00:25:38.680"><day>07</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Orthopaedic Surgery</italic> published by Tianjin Hospital and John Wiley &amp; Sons Australia, Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="OS-17-2960.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:OS-17-2960.pdf"/><abstract><title>ABSTRACT</title><sec id="os70150-sec-0001"><title>Objective</title><p>Intervertebral disc degeneration (IVDD) has been closely associated with ferroptosis in nucleus pulposus cells (NPCs), the underlying regulatory mechanisms and therapeutic strategies remain poorly defined. This study aims to delineate how ginsenoside Rg3 mitigates IVDD progression through ferroptosis suppression, providing a basis for clinical translation.</p></sec><sec id="os70150-sec-0002"><title>Method</title><p>An erastin&#8208;induced nucleus pulposus cell ferroptosis model was established. Suitable Erastin concentrations (0&#8211;20&#8201;&#956;M) were screened via CCK&#8208;8, qRT&#8208;PCR, and Western blotting based on viability, extracellular matrix (COL2A1/ACAN/ADAMTS5/MMP3) and ferroptosis markers (GPX4/FTH&#8208;1/ACSL4), followed by determination of optimal Rg3 concentrations (0&#8211;150&#8201;&#956;M) using identical methods. Key targets of Rg3 were predicted through network pharmacology and verified by qRT&#8208;PCR and Western blotting. After establishing a rat tail puncture&#8208;induced IVDD model, local injection of Rg3 was administered. Therapeutic efficacy was evaluated by MRI assessment of nucleus pulposus status and disc height, alongside histological and immunohistochemical analyses of Rg3's role in delaying disc degeneration.</p></sec><sec id="os70150-sec-0003"><title>Result</title><p>5&#8201;&#956;M Erastin effectively induced ferroptosis in nucleus pulposus cells, reducing cell viability, suppressing expression of extracellular matrix anabolic proteins (COL2A1, ACAN), while promoting catabolic factors (MMP3, ADAMTS5) and downregulating ferroptosis inhibitors (GPX4, FTH&#8208;1). These alterations were significantly reversed by 100&#8201;&#956;M Rg3. Integrated network pharmacology and molecular biological validation identified PRKAA2 as the key target mediating Rg3's anti&#8208;degenerative effects. In&#160;vivo rat experiments demonstrated that Rg3 treatment preserved disc height and attenuated disc degeneration, with histological and immunohistochemical analyses further confirming its therapeutic efficacy and PRKAA2&#8208;targeted regulation.</p></sec><sec id="os70150-sec-0004"><title>Conclusion</title><p>This study elucidates the therapeutic mechanism of Rg3 in delaying IVDD progression via PRKAA2&#8208;mediated ferroptosis inhibition, providing substantial experimental evidence for its clinical translation as a potential disease&#8208;modifying agent.</p></sec></abstract><abstract abstract-type="graphical"><p>Ginsenosides Rg3 were used to repair the degenerative nucleus pulposus; Furthermore, Rg3 was identified as the bioactive molecule that inhibits the occurrence of ferroptosis through inhibiting PRKAA2 expression in degenerated discs.<boxed-text position="anchor" content-type="graphic" id="os70150-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="OS-17-2960-g002.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="os70150-kwd-0001">ferroptosis</kwd><kwd id="os70150-kwd-0002">ginsenoside Rg3</kwd><kwd id="os70150-kwd-0003">intervertebral disc degeneration</kwd><kwd id="os70150-kwd-0004">network pharmacology</kwd><kwd id="os70150-kwd-0005">PRKAA2</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Innovation Training Program for College Students of North China University of Science and Technology</institution></institution-wrap></funding-source><award-id>X2023085</award-id></award-group></funding-group><counts><fig-count count="6"/><table-count count="0"/><page-count count="13"/><word-count count="6400"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:05.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="os70150-cit-1001"><string-name name-style="western"><given-names>W.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Geng</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Zhang</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, &#8220;<article-title>Targeting Ferroptosis With Ginsenoside Rg3 Alleviates Intervertebral Disc Degeneration</article-title>,&#8221; <source>Orthopaedic Surgery</source><volume>17</volume>, no. <issue>10</issue> (<year>2025</year>): <fpage>2960</fpage>&#8211;<lpage>2972</lpage>, <pub-id pub-id-type="doi">10.1111/os.70150</pub-id>.<pub-id pub-id-type="pmid">40852892</pub-id><pub-id pub-id-type="pmcid">PMC12497545</pub-id></mixed-citation>
</p><fn-group id="os70150-ntgp-0001"><fn fn-type="funding" id="os70150-note-0001"><p>
<bold>Funding:</bold> This work was supported by the Innovation Training Program for College Students of North China University of Science and Technology (X2023085).</p></fn></fn-group></notes></front><body id="os70150-body-0001"><sec id="os70150-sec-0005"><label>1</label><title>Introduction</title><p>Intervertebral disc degeneration (IVDD), a prevalent degenerative spinal disorder, serves as the primary pathological basis for chronic low back pain and a major public health concern contributing to neurological dysfunction and socioeconomic burdens [<xref rid="os70150-bib-0001" ref-type="bibr">1</xref>, <xref rid="os70150-bib-0002" ref-type="bibr">2</xref>, <xref rid="os70150-bib-0003" ref-type="bibr">3</xref>, <xref rid="os70150-bib-0004" ref-type="bibr">4</xref>]. Current therapeutic strategies, including conservative treatments (non&#8208;steroidal anti&#8208;inflammatory drugs, physical therapy) for transient symptom relief and surgical interventions to decompress neural structures, have failed to halt disease progression and carry recurrence risks [<xref rid="os70150-bib-0005" ref-type="bibr">5</xref>, <xref rid="os70150-bib-0006" ref-type="bibr">6</xref>, <xref rid="os70150-bib-0007" ref-type="bibr">7</xref>]. These limitations underscore the urgent need for novel therapies targeting IVDD pathogenesis.</p><p>The progression of IVDD is closely linked to nucleus pulposus cells (NPCs) dysfunction and extracellular matrix (ECM) metabolic imbalance [<xref rid="os70150-bib-0008" ref-type="bibr">8</xref>]. NPCs, responsible for maintaining intervertebral disc hydration and mechanical buffering, reside in a unique microenvironment characterized by hypoxia, low vascularity, and high mechanical stress [<xref rid="os70150-bib-0009" ref-type="bibr">9</xref>, <xref rid="os70150-bib-0010" ref-type="bibr">10</xref>]. This hostile niche renders NPCs highly dependent on antioxidant defenses to counteract oxidative damage. However, their limited capacity to scavenge reactive oxygen species (ROS) and lipid peroxidation byproducts predisposes them to programmed cell death [<xref rid="os70150-bib-0011" ref-type="bibr">11</xref>, <xref rid="os70150-bib-0012" ref-type="bibr">12</xref>, <xref rid="os70150-bib-0013" ref-type="bibr">13</xref>]. In recent years, ferroptosis, an iron&#8208;dependent, non&#8208;apoptotic programmed cell death, has been confirmed to be deeply involved in the pathological process of IVDD due to its unique driving mechanism of lipid peroxidation [<xref rid="os70150-bib-0014" ref-type="bibr">14</xref>, <xref rid="os70150-bib-0015" ref-type="bibr">15</xref>]. Studies have identified marked activation of ferroptosis features in degenerated intervertebral discs, including suppressed glutathione peroxidase 4 (GPX4) activity, increased mitochondrial membrane density, and abnormal accumulation of lipid peroxides [<xref rid="os70150-bib-0016" ref-type="bibr">16</xref>, <xref rid="os70150-bib-0017" ref-type="bibr">17</xref>]. Distinct from caspase&#8208;dependent apoptosis and inflammasome&#8208;driven pyroptosis, ferroptosis is characterized by mitochondrial cristae disappearance, absence of apoptotic bodies, and specific inhibition by Ferrostatin&#8208;1, without the pyroptosis&#8208;associated cytokine storm. This iron metabolism&#8208;dysregulated death pathway is markedly amplified in the hypoxic, nutrient&#8208;poor disc microenvironment, establishing it as a critical therapeutic target for retarding degenerative progression. However, systematic studies on the regulatory mechanisms of ferroptosis in IVDD and potential therapeutic targets are still lacking.</p><p>Ginsenoside Rg3, a core bioactive compound in Panax ginseng, demonstrates multi&#8208;target therapeutic potential through its antioxidant, anti&#8208;inflammatory, and multi&#8208;pathway regulatory properties&#160;[<xref rid="os70150-bib-0018" ref-type="bibr">18</xref>, <xref rid="os70150-bib-0019" ref-type="bibr">19</xref>]. Studies have shown that Rg3 inhibits ferroptosis via NRF2/HO&#8208;1 activation in acute pancreatitis [<xref rid="os70150-bib-0020" ref-type="bibr">20</xref>], modulates bone metabolism through AMPK/mTOR signaling in osteoporosis [<xref rid="os70150-bib-0021" ref-type="bibr">21</xref>], and alleviates myocardial injury through NF&#8208;&#954;B&#8208;mediated downregulation of IL&#8208;6/IL&#8208;1&#946;/TNF&#8208;&#945; secretion [<xref rid="os70150-bib-0022" ref-type="bibr">22</xref>], coupled with bidirectional regulation of oxidative stress markers (simultaneous SOD upregulation and ROS suppression) [<xref rid="os70150-bib-0023" ref-type="bibr">23</xref>, <xref rid="os70150-bib-0024" ref-type="bibr">24</xref>, <xref rid="os70150-bib-0025" ref-type="bibr">25</xref>]. However, whether Rg3 can specifically target ferroptosis pathways in oxidatively stressed NPCs to disrupt the oxidative stress cascade and thereby delay IVDD progression remains unexplored.</p><p>In this study, we established an erastin&#8208;induced NPCs ferroptosis model to verify the regulatory effect of Rg3 on ferroptosis and oxidative stress in NPCs. The potential targets of Rg3 were identified by network pharmacology analysis and verified by in&#160;vitro experiments. Finally, we evaluated the therapeutic efficacy of Rg3 in&#160;vivo using a rat tail needle puncture&#8208;induced disc degeneration model. This study not only provides novel evidence elucidating the pathological role of ferroptosis in IVDD but also establishes an experimental foundation for developing ferroptosis&#8208;targeted therapeutic strategies against disc degeneration.</p></sec><sec sec-type="materials-and-methods" id="os70150-sec-0006"><label>2</label><title>Materials and Methods</title><sec id="os70150-sec-0007"><label>2.1</label><title>Isolation and Culture of Rat <styled-content style="fixed-case" toggle="no">NPCs</styled-content>
</title><p>Primary nucleus pulposus cells were extracted from 6 to 8&#8208;week&#8208;old SD rats (SPF (Beijing) Biotechnology Co. Ltd., China). Following anesthesia with intraperitoneal administration of sodium pentobarbital (45&#8201;mg/kg), 10 rats (SPF (Beijing) Biotechnology Co. Ltd.) were humanely euthanized via cervical dislocation and subsequently sterilized by immersion in 75% ethanol for 15&#8201;min. The skin and ligament tissues were incised using sterile blades to expose the intervertebral discs. The nucleus pulposus tissues were picked and collected under sterile conditions after incising the annulus fibrosus, and placed in 0.2% type II collagenase (Solarbio, Beijing) for digestion for 5&#8201;h. During this period, the mixture was shaken every 30&#8201;min. After 5&#8201;h, DMEM/F12 (Gibco, Grand Island, NY, USA) complete medium was added to terminate the digestion. NPCs were cultured in DMEM/F&#8208;12 supplemented with 15% fetal bovine serum (FBS; Gibco), and 100&#8201;U/mL penicillin and 100&#8201;U/mL streptomycin at passage 0. After the first cell passage, NPCs were subsequently cultured in DMEM/F&#8208;12 supplemented with 10% FBS, and 100&#8201;U/mL penicillin and 100&#8201;U/mL streptomycin. All cells were cultured in a biological incubator at 37&#176;C and 5% CO<sub>2</sub>. NPCs at third passage were used for subsequent in&#160;vitro experiments.</p></sec><sec id="os70150-sec-0008"><label>2.2</label><title>Cell Viability</title><p>Cell Counting Kit&#8208;8 (CCK&#8208;8, Biosharp, China) assays were used to estimate the viability of NPCs according to the manufacturer's protocols. The absorbance of supernatants was determined at 450&#8201;nm with a microplate reader.</p></sec><sec id="os70150-sec-0009"><label>2.3</label><title>Quantitative Real&#8208;Time <styled-content style="fixed-case" toggle="no">PCR</styled-content> Analysis</title><p>Reverse transcriptase quantitative real&#8208;time polymerase chain reaction (RT&#8208;qPCR) was performed as previously reported [<xref rid="os70150-bib-0026" ref-type="bibr">26</xref>]. Briefly, total RNA was extracted with Trizol Reagent (Invitrogen). The concentration and purity of RNA were determined using a Scandrop device, and reverse transcription to cDNA was completed using the Hifair III 1st Strand cDNA Synthesis SuperMix kit (Yeasen, China). RT&#8208;qPCR analysis was performed using the SYBR Premix ExTaq II kit (TaKaRa, Japan) and detected on a Roche LightCycler 480 sequence detection system. GAPDH was used as a control gene. The 2<sup>&#8722;&#916;&#916;Ct</sup> method was conducted to calculate the relative expression of each gene. Cycle threshold (Ct) was defined as the amplification cycle when real&#8208;time fluorescence intensity of the reaction reached the set threshold. The primer sequences are listed in Table&#160;<xref rid="os70150-supitem-0001" ref-type="supplementary-material">S1</xref>.</p></sec><sec id="os70150-sec-0010"><label>2.4</label><title>Western Blotting Analysis</title><p>NPCs were homogenized and lysed in RIPA lysis buffer (Cwbio, China) on ice for 20&#8201;min and then centrifuged at 10,000&#8201;g for 15&#8201;min. The concentration of total protein samples was measured using the BCA Protein Assay Kit (Uelandy, China). The lysates of NPCs were diluted at a ratio of 1:5 with 5&#215; loading buffer and heated at 100&#176;C for 15&#8201;min. The protein mixture was loaded into the wells of 10% SDS&#8208;PAGE gels for electrophoresis at 120&#8201;V for 1.5&#8201;h before transfer onto a polyvinylidene fluoride (PVDF) membrane (Merck&#8208;Millipore) for 1&#8201;h at 300&#8201;mA. After blocking for 1&#8201;h with 5% non&#8208;fat dried milk in TBST, the PVDF membranes were incubated with primary antibodies (Abcam plc, UK) at 4&#176;C overnight. Next, after three 10&#8208;min washes in TBST buffer, the transferred PVDF membranes were incubated with HRP&#8208;conjugated IgG secondary antibodies (Abcam plc, UK) for 1&#8201;h at 37&#176;C with gentle shaking. Finally, after three 10&#8208;min washes in TBST buffer, the membranes were probed with Super ECL Plus (Uelandy, China) and monitored on Amersham Imager 600.</p></sec><sec id="os70150-sec-0011"><label>2.5</label><title>Establishment of the <styled-content style="fixed-case" toggle="no">NPCs</styled-content> Ferroptosis Model</title><p>To generate a model of ferroptosis of NPCs, the cells were treated with different concentrations of erastin (1, 2, 5, 10, and 20&#8201;&#956;M) with parallel vehicle controls (DMSO) for 10&#8201;h. CCK8 proliferation assay was used to measure the cellular vitality. The expression of extracellular matrix synthesis and catabolism and ferroptosis&#8208;related proteins and mRNA (ACAN, Col2A1, ADAMTS&#8208;5, MMP3, GPX4, FTH&#8208;1) in NPCs was detected by Western blotting and RT&#8208;qPCR. The optimal concentration of erastin was determined through integrated analysis of viability suppression, extracellular matrix homeostasis disruption, and ferroptosis biomarker activation patterns.</p></sec><sec id="os70150-sec-0012"><label>2.6</label><title>Effects of Different Concentrations of Rg3 on <styled-content style="fixed-case" toggle="no">NPCs</styled-content> Treated With Erastin In&#160;Vitro</title><p>NPCs were treated with varying concentrations of Rg3 (0, 50, 100, 150&#8201;&#956;M) and the cell viability was assessed using the CCK&#8208;8 assay to evaluate potential cytotoxic effects. Subsequently, the mRNA expression levels of genes associated with extracellular matrix synthesis (ACAN, COL2A1), catabolism (ADAMTS5, MMP3), and ferroptosis (GPX4, FTH1) were measured by qRT&#8208;PCR, while Western Blotting analysis was performed to assess the corresponding protein expression levels.</p></sec><sec id="os70150-sec-0013"><label>2.7</label><title>Effects of Rg3 on <styled-content style="fixed-case" toggle="no">NPCs</styled-content> Treated With Erastin In&#160;Vitro</title><p>NPCs were treated with appropriate concentrations of Rg3 and Erastin, and the TCP cells were set as control. Cell viability was evaluated using the CCK&#8208;8 assay to assess the inhibitory effect of Rg3 on Erastin&#8208;induced ferroptosis. Subsequently, the mRNA expression levels of genes associated with extracellular matrix synthesis (ACAN, COL2A1), catabolism (ADAMTS5, MMP3), and ferroptosis (GPX4, FTH1, ACSL4) were measured by qRT&#8208;PCR, while Western Blotting analysis was performed to assess the corresponding protein expression levels.</p></sec><sec id="os70150-sec-0014"><label>2.8</label><title>Network Pharmacology Analysis With Rg3</title><p>The potential therapeutic targets of Rg3 were initially predicted using SwissTargetPrediction and Similarity Ensemble Approach (SEA) databases. For IVDD profiling, transcriptomic analysis of the GEO dataset <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE266883">GSE266883</ext-link> was conducted via DESeq2 in R, identifying differentially expressed genes (DEGs) between pathological and normal specimens with thresholds set at |logFC| &gt;&#8201;1 and adjusted <italic toggle="yes">p</italic>&#8208;value &lt;&#8201;0.05. Data visualization was achieved through ggplot2 (volcano plots), pheatmap (hierarchical clustering), and ggvenn (intersection diagrams).</p><p>Protein&#8211;protein interaction networks were reconstructed by importing IVDD&#8208;associated targets into the STRING database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cn.string-db.org/" ext-link-type="uri">https://cn.string&#8208;db.org/</ext-link>), followed by topological analysis using igraph and ggnetwork packages in R. Functional enrichment analysis via clusterProfiler revealed biologically relevant pathways, with the top 10 GO terms and KEGG pathways visualized through Sankey&#8208;bubble integration plots. Ferroptosis pathway activity was quantified using single&#8208;sample gene set enrichment analysis (ssGSEA) based on KEGG&#8208;defined ferroptosis genes, with subsequent Spearman's correlation analysis linking pathway scores to expression patterns of key targets.</p><p>Finally, molecular docking simulations focused on prioritized targets were performed in AutoDock Vina. Active sites predicted by DoGSiteScorer guided docking parameter configuration, with PyMOL rendering the three&#8208;dimensional binding conformations and interaction profiles.</p></sec><sec id="os70150-sec-0015"><label>2.9</label><title>Animal Models and Surgical Procedures</title><p>All experimental procedures involving animals were conducted in strict compliance with the Institutional Animal Care and Use Committee (IACUC) guidelines and approved by the Animal Research Ethics Committee of Tianjin hospital (2025&#8208;057). 12&#8208;week&#8208;old male Sprague&#8211;Dawley (SD) rats (SPF (Beijing) Biotechnology Co. Ltd.) weighing 250&#8201;&#177;&#8201;20&#8201;g were used for animal models. Rat tail needle puncture&#8208;induced IVDD models were generated as previously described [<xref rid="os70150-bib-0027" ref-type="bibr">27</xref>]. In brief, the rats were initially anesthetized in an induction chamber with 3% isoflurane. Upon achieving surgical&#8208;plane anesthesia, anesthesia was maintained with 1.5% isoflurane via a nose cone delivery system. The intervertebral spaces of coccygeal discs (Co) were exposed (Co 4&#8211;7). From the 10 experimental rats, a total of 30 intervertebral discs (3 discs per animal, 10 discs per group) were randomly allocated into three experimental groups: Control, IVDD, and Rg3 group. All animals were uniquely identified using coded ear tags prior to grouping. To induce IVDD in rat caudal, an 18&#8208;gauge syringe needle was inserted 3&#8201;mm into each disc, rotated 90&#176; clockwise, and held in position for 30&#8201;s. To verify the effect of Rg3, 10 &#956;L of 100 &#956;M Rg3 solution was injected into the intervertebral disc. Following random allocation into polycarbonate cages (five rats per cage), animals were acclimatized for 7&#8201;days under specific pathogen&#8208;free (SPF) conditions. During this period, rats were fed a standardized irradiated pellet diet with ad&#160;libitum access to reverse&#8208;osmosis purified water. Environmental parameters were strictly maintained at 23&#176;C&#8201;&#177;&#8201;1&#176;C with 50%&#8201;&#177;&#8201;10% relative humidity and a 12:12&#8201;h light&#8211;dark cycle. T2 Magnetic resonance imaging (MRI) was used to determine whether the models were successful in inducing IVDD. T2 MRI was performed at 8&#8201;weeks postoperatively and histological analysis was evaluated after harvesting. All 10 rats successfully completed the 8&#8208;week experimental timeline with no rats experiencing unintended mortality.</p></sec><sec id="os70150-sec-0016"><label>2.10</label><title>
<styled-content style="fixed-case" toggle="no">MRI</styled-content> Acquisition and Analysis</title><p>At postoperative week 8, rats were anesthetized via intraperitoneal injection of sodium pentobarbital (45&#8201;mg/kg) and maintained under stable anesthesia. T2&#8208;weighted midsagittal sections were obtained using a 3.0&#8208;T MRI scanner. The rat was fixed onto a small&#8208;animal MRI coil. The region of the rat tail was used as a region of interest for scanning. The MRI scan parameters were as follows: spin echo repetition time, 2275&#8201;ms; echo time, 80&#8201;ms; number of excitations, 8; field of view, 5&#8201;cm; slice thickness, 1.5&#8201;mm. The change in IVD height was then quantified using the intervertebral disc height index (DHI) according to previous reports [<xref rid="os70150-bib-0028" ref-type="bibr">28</xref>]. The Pfirrmann MRI grading score was used to analyze the degeneration of the nucleus pulposus.</p></sec><sec id="os70150-sec-0017"><label>2.11</label><title>Histological Analysis</title><p>Following in&#160;vivo MRI evaluation, rats were humanely euthanized via intraperitoneal administration of pentobarbital sodium (100&#8201;mg/kg) to ensure complete anesthetic overdose. Spinal motion segments were then surgically excised and immersion&#8208;fixed in 4% paraformaldehyde for 1&#8201;day; samples were decalcified with EDTA for 8&#8201;weeks before sectioning. After dehydration with gradient alcohol concentrations (70% to 100%) and paraffin embedding, the intervertebral disc (IVD) samples were cut into 5&#8201;&#956;m&#8208;thick coronal sections using a microtome (Leica RM2235) and mounted on anti&#8208;slip slides. Serial sections were stained with H&amp;E to observe cell morphology and Safranin&#8208;O/Fast Green to analyze proteoglycan and collagen distribution. The slides were then observed under an upright light microscope (Leica DM3000, Germany). Two pathologists blinded to experimental groups evaluated the results according to the Rutges histological scoring criteria based on cellularity of AF, the morphology of AF, AF&#8208;NP border, cellularity of NP, and morphology of NP [<xref rid="os70150-bib-0029" ref-type="bibr">29</xref>]. Representative paraffin sections were deparaffinized, rehydrated, and subjected to heat&#8208;induced antigen retrieval in sodium citrate buffer (10&#8201;mM, pH&#8201;6.0) at 95&#176;C for 20&#8201;min. After blocking with 5% goat serum, sections were incubated with mouse anti&#8208;PRKAA2 antibody (Cat# HY&#8208;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="P84394">P84394</ext-link>, 1:200) overnight at 4&#176;C, followed by HRP&#8208;conjugated goat anti&#8208;mouse IgG (1:200) for 2&#8201;h at RT. DAB chromogen and hematoxylin counterstaining were applied. Quantification of PRKAA2&#8208;positive area percentage was performed using ImageJ after imaging.</p></sec><sec id="os70150-sec-0018"><label>2.12</label><title>Statistical Analysis</title><p>All data were expressed as the mean&#8201;&#177;&#8201;standard deviation (SD). One&#8208;way ANOVA, two&#8208;way ANOVA, and Tukey&#8211;Kramer tests were applied for multigroup comparisons. Unpaired Student's t&#8208;test or Pearson's chi&#8208;squared test were used for comparisons between two groups. All statistical analyses were performed using GraphPad Prism Software v9.0 (San Diego, CA, USA). The minimum significance levels were set at *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, and ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, ****<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001, ns: no significance, and these are indicated on the relevant figures.</p></sec></sec><sec sec-type="results" id="os70150-sec-0019"><label>3</label><title>Results</title><sec id="os70150-sec-0020"><label>3.1</label><title>Establishment of the <styled-content style="fixed-case" toggle="no">NPCs</styled-content> Ferroptosis Model</title><p>To determine the optimal ferroptosis&#8208;inducing concentration of Erastin, NPCs were subjected to a pharmacological gradient (1&#8211;20&#8201;&#956;M) with parallel vehicle controls. Quantitative CCK&#8208;8 viability profiling revealed a statistically significant concentration&#8208;dependent decrease in cellular viability (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05), confirming Erastin's dose&#8208;responsive cytotoxicity in NPCs (Figure&#160;<xref rid="os70150-fig-0001" ref-type="fig">1A</xref>). Furthermore, qRT&#8208;PCR and Western blotting analysis demonstrated coordinated molecular alterations in Erastin&#8208;treated NPCs characterized by concurrent suppression of extracellular matrix anabolic markers (ACAN, COL2A1) and elevation of catabolic regulators (ADAMTS&#8208;5, MMP3). The ferroptotic response was further confirmed through dose&#8208;dependent modulation of GPX4 axis components, showing progressive GPX4 and FTH&#8208;1 depletion across increasing erastin concentrations. These findings collectively validate the establishment of a functional ferroptosis model exhibiting concentration&#8208;responsive ECM remodeling and ferroptotic pathway activation. 5&#8201;&#956;M erastin effectively triggers ferroptosis&#8208;specific phenotypes, characterized by downregulation of extracellular matrix anabolic genes and upregulation of catabolic genes, alongside elevated ferroptosis markers. Crucially, this concentration maintains high cell viability while inducing ferroptosis, optimally balancing model specificity and cellular survival. Hence, we selected 5&#8201;&#956;M erastin to induce ferroptosis in NPCs for subsequent experiments.</p><fig position="float" fig-type="FIGURE" id="os70150-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Dose&#8211;response regulation of Erastin in NPCs. (A) CCK8 assay detect the effect of Erastin on NPCs. (B&#8211;H) Regulation effects of various concentrations of Erastin on gene expression in NPCs (<italic toggle="yes">n</italic>&#8201;=&#8201;4 biologically independent samples). I&#8208;N) Regulation effects of various concentrations of erastin on protein expression in NPCs. (<italic toggle="yes">n</italic>&#8201;=&#8201;3 biologically independent samples) *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, ****<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001, ns, no significance.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="OS-17-2960-g005.jpg"/></fig></sec><sec id="os70150-sec-0021"><label>3.2</label><title>Rg3 Inhibits Erastin&#8208;Induced Ferroptosis in <styled-content style="fixed-case" toggle="no">NPCs</styled-content>
</title><p>To investigate the ferroptosis&#8208;inhibitory potential of ginsenoside Rg3, nucleus pulposus cells (NPCs) preconditioned with 20&#8201;&#956;M Erastin underwent pharmacological intervention with increasing Rg3 concentrations (50, 100, 150&#8201;&#956;M). Quantitative CCK&#8208;8 analysis demonstrated dose&#8208;responsive cytoprotection, wherein Rg3 treatment significantly rescued erastin&#8208;induced viability loss in a concentration&#8208;dependent manner (Figure&#160;<xref rid="os70150-fig-0002" ref-type="fig">2A</xref>). qRT&#8208;PCR (Figure&#160;<xref rid="os70150-fig-0002" ref-type="fig">2B&#8211;H</xref>) and WB (Figure&#160;<xref rid="os70150-fig-0002" ref-type="fig">2I&#8211;O</xref>) further verified the concentration&#8208;dependent inhibitory effect of Rg3 on erastin&#8208;induced ferroptosis at the protein and gene levels, respectively. Rg3 dose&#8208;dependently rescued erastin&#8208;induced downregulation of extracellular matrix anabolic markers (ACAN, Col2A1) while attenuating pathological upregulation of matrix catabolic regulators (ADAMTS&#8208;5, MMP3). In terms of ferroptosis&#8208;related proteins, Rg3 administration coordinately modulated core ferroptosis regulators&#8212;suppressing GPX4 and FTH1 protein levels. This molecular signature confirms Rg3's dual regulatory capacity in counteracting both matrix degeneration and ferroptotic cascades. 100&#8201;&#956;M Rg3 demonstrated optimal intervention outcomes in both extracellular matrix remodeling and regulation of ferroptosis, and was therefore selected for subsequent mechanistic interrogation of ferroptosis modulation.</p><fig position="float" fig-type="FIGURE" id="os70150-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Dose&#8211;response regulation of Rg3 on Erastin&#8208;induced pathophenotypes in NPCs. (A) CCK8 assay detects the effect of Rg3 on NPCs. (B&#8211;H) Regulation effects of various concentrations of Rg3 on gene expression in Erastin&#8208;treated NPCs. (I&#8211;O) Regulation effects of various concentrations of Rg3 on protein expression in erastin&#8208;treated NPCs. (<italic toggle="yes">n</italic>&#8201;=&#8201;3 biologically independent samples) *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, ****<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001, ns, no significance.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="OS-17-2960-g006.jpg"/></fig><p>To further confirm the regulatory effect of Rg3 on ferroptosis in NPCs, we treated Erastin&#8208;induced NPCs with 100&#8201;&#956;M Rg3 (TCP as control, Figure&#160;<xref rid="os70150-fig-0003" ref-type="fig">3</xref>). The CCK&#8208;8 assay demonstrated that 100&#8201;&#956;M Rg3 effectively reversed Erastin&#8208;triggered cell death and restored proliferation viability. qRT&#8208;PCR analysis revealed that Rg3 preserved extracellular matrix anabolic gene expression (ACAN and COL2A1), suppressed catabolic gene expression (ADAMTS5 and MMP3), upregulated ferroptosis&#8208;related genes (FTH1 and GPX4). Western blotting results further corroborated these transcriptional changes at the protein level. Besides, the results demonstrate that Rg3 significantly inhibits the erastin&#8208;induced upregulation of ACSL4, collectively indicating the anti&#8208;ferroptotic potential of Rg3 in this model.</p><fig position="float" fig-type="FIGURE" id="os70150-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Rg3 inhibits erastin&#8208;induced ferroptosis in NPCs. (A) CCK8 assay detects the effect of Rg3 on the erastin&#8208;induced proliferation of NPCs. (B&#8211;G) Regulatory effects of Rg3 on gene expression in erastin&#8208;treated NPCs. (H&#8211;O) Regulatory effects of Rg3 on protein expression in erastin&#8208;treated NPCs. (<italic toggle="yes">n</italic>&#8201;=&#8201;3 biologically independent samples) *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, ****<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001, ns, no significance.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="OS-17-2960-g003.jpg"/></fig></sec><sec id="os70150-sec-0022"><label>3.3</label><title>Rg3 Inhibits the Ferroptosis of <styled-content style="fixed-case" toggle="no">NPCs</styled-content> via Regulating the Expression of <styled-content style="fixed-case" toggle="no">PRKAA2</styled-content>
</title><p>Systematic pharmacological prediction using SwissTargetPrediction (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://swisstargetprediction.ch/" ext-link-type="uri">http://swisstargetprediction.ch/</ext-link>) and SEA databases (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://sea.bkslab.org/" ext-link-type="uri">https://sea.bkslab.org/</ext-link>) identified 27 putative molecular targets of Rg3. For IVDD profiling, bioinformatic analysis of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE266883">GSE266883</ext-link> dataset through DESeq2 revealed 2178 upregulated and 1577 downregulated differentially expressed genes (DEGs) in degenerative specimens compared to healthy controls, establishing a molecular signature of IVDD progression (Figure&#160;<xref rid="os70150-fig-0004" ref-type="fig">4A</xref>). Cross&#8208;referencing these disease&#8208;associated DEGs with Rg3's predicted targets yielded nine intersecting genes demonstrating dual regulatory potential (Figure&#160;<xref rid="os70150-fig-0004" ref-type="fig">4B,C</xref>), of which &#8220;RORC, HSD11B1, PRKAA2, and APH1B&#8221; were up&#8208;regulated and &#8220;LGALS9, FGF1, CDK1, FGF2, F3&#8221; were down&#8208;regulated in degenerative intervertebral disc tissues. Protein interaction network construction via STRING database revealed functional connectivity among all targets except APH1B, with topological centrality analysis identifying FGF2 as the predominant hub node governing network architecture, as evidenced by its highest betweenness centrality score in the visualized interactome (Figure&#160;<xref rid="os70150-fig-0004" ref-type="fig">4D</xref>).</p><fig position="float" fig-type="FIGURE" id="os70150-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Network pharmacology analysis of Rg3 in IVDD. (A) Volcano plot displaying differentially expressed genes in IVDD. (B) Venn diagram showing overlapping targets between Rg3 and IVDD&#8208;related genes. (C) Heatmap of expression patterns for Rg3&#8208;IVDD&#8208;associated targets. (D) Protein&#8211;protein interaction network of Rg3 and IVDD&#8208;related targets. (E) Sankey diagram illustrating KEGG pathway enrichment analysis. (F, G) Raincloud plots presenting ferroptosis scores in IVDD samples. (H) Molecular docking model of Rg3 with PRKAA2. (I) qRT&#8208;PCR analysis of PRKAA2 expression under Erastin and Rg3 treatment. (J, K) WB and quantification of PRKAA2 protein levels with Erastin and Rg3 intervention (<italic toggle="yes">n</italic>&#8201;=&#8201;3 biologically independent samples). *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, ****<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001, ns, no significance.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="OS-17-2960-g004.jpg"/></fig><p>Functional enrichment analysis through KEGG pathways elucidated the biological relevance of Rg3 targets, with results visualized in an integrated Sankey&#8208;bubble diagram. KEGG pathway enrichment analysis demonstrated Rg3's mechanistic engagement with the PI3K&#8208;AKT signaling pathway, MAPK signaling pathway, Calcium signaling pathway, and Ras signaling pathway, and so forth (Figure&#160;<xref rid="os70150-fig-0004" ref-type="fig">4E</xref>). To investigate ferroptosis involvement in IVDD, pathway enrichment analysis was performed using the single&#8208;sample Gene Set Variation Analysis (GSEA) algorithm within the GSVA package, leveraging the ferroptosis&#8208;related gene set from the KEGG database. Comparative analysis revealed significantly elevated ferroptosis pathway activity scores in IVDD specimens compared to healthy controls (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (Figure&#160;<xref rid="os70150-fig-0004" ref-type="fig">4F</xref>). Subsequent Spearman correlation analysis between these ferroptosis scores and the expression levels of the top 10 KEGG pathway&#8208;associated targets identified PRKAA2 as the most strongly correlated gene, demonstrating a robust positive association (p&#8201;&lt;&#8201;0.05) (Figure&#160;<xref rid="os70150-fig-0004" ref-type="fig">4G</xref>). To validate the network&#8208;predicted interactions, computational molecular docking was performed on PRKAA2 using AutoDock Vina (Figure&#160;<xref rid="os70150-fig-0004" ref-type="fig">4H</xref>). Structural analyses revealed favorable binding affinities between Rg3 and PRKAA2 (binding energy: &#8722;7.341&#8201;kcal/mol).</p><p>Subsequently, we studied the changes of PRKAA2 expression levels in NPCs treated with erastin and Rg3. The results showed that the expression level of PRKAA2 was significantly up&#8208;regulated in the erastin group, and the effect was effectively reversed by Rg3 (Figure&#160;<xref rid="os70150-fig-0004" ref-type="fig">4I</xref>). Western blotting showed that NPCs incubated with Rg3 had inhibited the production of PRKAA2, while co&#8208;treatment with the Rg3 inhibitor reestablished the production of PRKAA2 protein (Figure&#160;<xref rid="os70150-fig-0004" ref-type="fig">4J,K</xref>).</p><p>Rg3 alleviates IVDD by inhibiting ferroptosis in&#160;vivo.</p><p>The therapeutic effects of Rg3 were evaluated in puncture&#8208;induced rat coccygeal IVDD models. After 8&#8201;weeks of surgery, MRI scans were used to evaluate the degree of rat coccygeal IVDD (Figure&#160;<xref rid="os70150-fig-0005" ref-type="fig">5A</xref>). Based on the MRI analysis, the height of the IVD in the IVDD group showed a significant reduction compared to the control group (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05); the Rg3 group exhibited a degree of disc compression but had retained disc height compared to the IVDD groups. T2&#8208;MRI images illustrated that the NP integrity and water content were better preserved in the Rg3 group than in the IVDD group. Consistent with these results, Pfirrmann grading also revealed that the Rg3 group had a reparative effect. Histological sections were obtained at 8&#8201;weeks post&#8208;operation. H&amp;E and Saffron O&#8208;Fast Green staining showed that the number of NPCs had decreased and the arrangement of ECM was disordered in the IVDD group. The damage to the tissue structure was partially alleviated in the Rg3 group compared with the IVDD group (Figure&#160;<xref rid="os70150-fig-0005" ref-type="fig">5D&#8211;F</xref>). To validate the PRKAA2&#8208;mediated mechanism underlying Rg3's protective effects against disc degeneration, immunohistochemical analysis revealed that PRKAA2 was highly expressed in the degenerated discs (Figure&#160;<xref rid="os70150-fig-0005" ref-type="fig">5G,H</xref>), consistent with our previous pharmacological findings. Notably, Rg3 treatment effectively attenuated disc degeneration progression while downregulating PRKAA2 expression.</p><fig position="float" fig-type="FIGURE" id="os70150-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>In vivo assessment of the role of Rg3. (A) T2 MRI at 8&#8201;weeks postoperatively. (B) Quantitative results of intervertebral disc height. (C) Quantitative results of Pfirrmann grade. (D) H&amp;E staining at 8&#8201;weeks postoperatively. (E) Safranin O and Fast Green staining at 8&#8201;weeks postoperatively. (F) Histological scoring of disc degeneration. (G, H) Immunohistochemical staining and quantitative results of the positive area of PRKAA2. (<italic toggle="yes">n</italic>&#8201;=&#8201;3 biologically independent samples) *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, ****<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001, ns, no significance.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="OS-17-2960-g001.jpg"/></fig></sec></sec><sec sec-type="discussion" id="os70150-sec-0023"><label>4</label><title>Discussion</title><sec id="os70150-sec-0024"><label>4.1</label><title>Ferroptosis in <styled-content style="fixed-case" toggle="no">IVDD</styled-content> Pathogenesis and Rg3 Intervention</title><p>IVDD represents a major socioeconomic burden as it serves as the primary contributor to spinal disorders and related morbidity [<xref rid="os70150-bib-0002" ref-type="bibr">2</xref>, <xref rid="os70150-bib-0030" ref-type="bibr">30</xref>]. The pathogenesis of IVDD involves the progressive disintegration of NPCs homeostasis and ECM metabolic dysregulation, driven by multifactorial interactions. Emerging evidence indicates that oxidative stress accumulation and subsequent inflammatory cascades disrupt cellular homeostasis and ECM integrity, constituting the core pathological features of IVDD [<xref rid="os70150-bib-0031" ref-type="bibr">31</xref>, <xref rid="os70150-bib-0032" ref-type="bibr">32</xref>]. These pathological processes establish a self&#8208;perpetuating tissue microenvironment characterized by chronic oxidative damage and compromised regenerative capacity, posing significant challenges to current therapeutic strategies [<xref rid="os70150-bib-0033" ref-type="bibr">33</xref>, <xref rid="os70150-bib-0034" ref-type="bibr">34</xref>]. Ferroptosis, a novel form of regulated cell death, is pathologically characterized by GPX4 inactivation, mitochondrial membrane hypercondensation, and pathological lipid peroxide accumulation [<xref rid="os70150-bib-0014" ref-type="bibr">14</xref>, <xref rid="os70150-bib-0017" ref-type="bibr">17</xref>]. Emerging evidence delineates this iron&#8208;dependent, lipid peroxidation driven non&#8208;apoptotic death modality as a critical contributor to IVDD pathogenesis. Investigations demonstrate marked activation of ferroptosis hallmarks in degenerative disc tissues, including suppressed GPX4 enzymatic activity, abnormally elevated mitochondrial membrane density, and excessive accumulation of lipid peroxidation byproducts [<xref rid="os70150-bib-0035" ref-type="bibr">35</xref>, <xref rid="os70150-bib-0036" ref-type="bibr">36</xref>]. Notably distinct from classical apoptosis or necrosis, ferroptosis disrupts the redox homeostasis of NPCs, initiating a self&#8208;amplifying &#8220;oxidative stress&#8208;mitochondrial dysfunction&#8208;ECM degradation&#8221; cascade that accelerates disc degeneration. These findings collectively suggest that therapeutic targeting of ferroptosis may represent a novel mechanistic strategy for IVDD intervention, offering dual modulation of oxidative damage and matrix remodeling pathways. In our study, results demonstrated that erastin, functioning as a ferroptosis inducer, significantly suppressed anabolic metabolism (COL2A1, ACAN) and promoted catabolic activity (ADAMTS5, MMP3) in nucleus pulposus cells, ultimately triggering cellular ferroptosis (GPX4, FTH&#8208;1).</p><p>Ginsenoside Rg3, a principal bioactive compound derived from Panax ginseng, exhibits multifaceted therapeutic properties through its antioxidant, anti&#8208;inflammatory, and multi&#8208;pathway regulatory mechanisms [<xref rid="os70150-bib-0020" ref-type="bibr">20</xref>, <xref rid="os70150-bib-0021" ref-type="bibr">21</xref>, <xref rid="os70150-bib-0024" ref-type="bibr">24</xref>]. Studies demonstrate that Rg3 modulates energy metabolism, inflammatory responses, and immune balance by targeting bile acid receptors, steroid hormone receptors, and ADP receptors [<xref rid="os70150-bib-0037" ref-type="bibr">37</xref>]. Its anti&#8208;tumor effects are particularly notable, with evidence showing that Rg3 suppressed angiogenesis by inhibiting VEGF signaling and enhances chemotherapy efficacy in hepatocellular carcinoma [<xref rid="os70150-bib-0038" ref-type="bibr">38</xref>]. In models of myocardial ischemia&#8211;reperfusion injury, Rg3 improves mitochondrial function by reducing ROS accumulation and lactate dehydrogenase release, while stabilizing calcium homeostasis through SUMOylation&#8208;mediated regulation of SERCA2a activity&#160;[<xref rid="os70150-bib-0039" ref-type="bibr">39</xref>]. Additionally, Rg3 demonstrates neuroprotective and anti&#8208;aging effects by attenuating NF&#8208;&#954;B&#8208;driven inflammatory responses, limiting ROS&#8208;induced cellular damage, and reducing the production of senescence&#8208;associated secretory phenotypes [<xref rid="os70150-bib-0040" ref-type="bibr">40</xref>]. These pleiotropic actions underscore Rg3's potential as a multi&#8208;target therapeutic agent for chronic diseases, bridging molecular mechanisms with translational applications. In our study, we established an in&#160;vitro ferroptosis model to investigate the therapeutic potential of Rg3. Through comprehensive assessment of molecular analyses via qPCR and Western blot revealed that Rg3 could maintain the balance of extracellular matrix synthesis and catabolism and effectively reverses aberrant expression of ferroptosis&#8208;associated genes and proteins, suggesting its regulatory role in core ferroptosis pathways to preserve nucleus pulposus cell functionality.</p><p>To elucidate the underlying molecular mechanisms, we integrated network pharmacology with molecular docking approaches, identifying the adenosine monophosphate&#8208;activated protein kinase &#945;2 subunit (PRKAA2/AMPK&#945;2) as a high&#8208;confidence target of Rg3. PRKAA2, a critical regulator of cellular energy metabolism, has been implicated in modulating autophagy and mitochondrial homeostasis in prior studies. Our findings propose a novel mechanism whereby Rg3&#8208;mediated PRKAA2 modulation may disrupt ferroptotic signaling cascades, offering fresh insights into the intersection of metabolic dysregulation and degenerative disc pathology.</p><p>Finally, we employed a rat caudal intervertebral disc needle&#8208;puncture degeneration model to comprehensively evaluate the therapeutic efficacy of Rg3 through multimodal imaging and histopathological assessments. T2&#8208;weighted MRI revealed notably preserved high signal intensity in the nucleus pulposus region of Rg3&#8208;treated discs, indicative of maintained hydration status and proteoglycan retention. Rg3 substantially ameliorated structural collapse, as evidenced by a significantly higher disc height index (DHI) percentage compared to degeneration controls. Histopathological evaluations, including H&amp;E and Safranin O&#8208;Fast Green staining, confirmed that Rg3 intervention restored disc boundary clarity between the NP and AF, attenuated extracellular matrix degradation, and increased nucleus pulposus cellularity relative to untreated degenerative discs. Immunohistochemical results revealed that Rg3 reduces PRKAA2 expression, confirming its therapeutic mechanism through this target in preventing ferroptosis and disc degeneration. Our in&#160;vivo experiments consistently demonstrated Rg3's ability to slow IVDD progression, showing similar anti&#8208;ferroptosis effects as observed in cell models. This therapeutic effect appears to operate through Rg3's suppression of PRKAA2&#8208;mediated ferroptosis pathways.</p></sec><sec id="os70150-sec-0025"><label>4.2</label><title>Strengths and Limitations</title><p>Our work not only establishes ferroptosis as a previously underappreciated pathological driver in IVDD but also positions Rg3 as a novel therapeutic candidate capable of simultaneously targeting matrix remodeling, energy metabolism, and ferroptosis. The study not only provides a novel natural drug candidate for delaying IVDD but also pioneers a therapeutic paradigm that reprograms the degenerative tissue microenvironment via multi&#8208;target aglycone compounds, thereby advancing traditional medicine toward precision and standardization in disc degeneration. However, our study has limitations: we did not investigate the pharmacokinetics of Rg3 in depth, nor did we further explore the regulatory mechanisms of PRKAA2.</p></sec><sec id="os70150-sec-0026"><label>4.3</label><title>Prospects of Clinical Application</title><p>Our findings demonstrate Rg3 delays IVDD progression in rats by targeting PRKAA2 to concurrently ameliorate ferroptosis and extracellular matrix dysregulation, supporting its therapeutic potential. Future work should prioritize disc&#8208;targeted delivery systems like sustained&#8208;release hydrogels to enhance bioavailability, validate PRKAA2 networks through CRISPR, and explore combination therapies with stem cells or growth factors. Furthermore, large animal studies confirming long&#8208;term efficacy and optimal dosing remain crucial for clinical translation.</p></sec></sec><sec sec-type="conclusions" id="os70150-sec-0027"><label>5</label><title>Conclusion</title><p>Our study establishes ferroptosis as a key pathological mechanism in IVDD and proposes Rg3 as a novel therapeutic agent targeting both matrix remodeling and ferroptosis through PRKAA2 modulation. Our work delivers a promising natural compound for delaying IVDD progression alongside a microenvironment&#8208;reprogramming strategy, advancing precision applications of traditional medicine in disc degeneration treatment.</p></sec><sec id="os70150-sec-0117"><title>Author Contributions</title><p>W.X., F.G., and K.Z. designed the study, performed the research and wrote the draft. W.X. and K.Z. collected data. F.G., Y.W. and K.Z. provided technical support and edited the paper. F.G. and Y.W. edited, supervised, and reviewed the paper. All authors contributed to the study and approved the final manuscript.</p></sec><sec sec-type="COI-statement" id="os70150-sec-0028"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="os70150-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Table&#160;S1:</bold> Sequence used in this study.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="OS-17-2960-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="os70150-sec-0029"><title>Acknowledgments</title><p>This work was supported by the Innovation Training Program for College Students of North China University of Science and Technology (X2023085).</p></ack><sec sec-type="data-availability" id="os70150-sec-0031"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="os70150-bibl-0001"><title>References</title><ref id="os70150-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="os70150-cit-0001"><string-name name-style="western"><given-names>T.</given-names><surname>Vos</surname></string-name>, <string-name name-style="western"><given-names>S. S.</given-names><surname>Lim</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Abbafati</surname></string-name>, et&#160;al., &#8220;<article-title>Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990&#8211;2019: A Systematic Analysis for the Global Burden of Disease Study 2019</article-title>,&#8221; <source>Lancet</source><volume>396</volume> (<year>2020</year>): <fpage>1204</fpage>&#8211;<lpage>1222</lpage>.<pub-id pub-id-type="pmid">33069326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30925-9</pub-id><pub-id pub-id-type="pmcid">PMC7567026</pub-id></mixed-citation></ref><ref id="os70150-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="os70150-cit-0002"><string-name name-style="western"><given-names>J.</given-names><surname>Hartvigsen</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Hancock</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Kongsted</surname></string-name>, et&#160;al., &#8220;<article-title>What Low Back Pain Is and Why We Need to Pay Attention</article-title>,&#8221; <source>Lancet</source><volume>391</volume> (<year>2018</year>): <fpage>2356</fpage>&#8211;<lpage>2367</lpage>.<pub-id pub-id-type="pmid">29573870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)30480-X</pub-id></mixed-citation></ref><ref id="os70150-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="os70150-cit-0003"><string-name name-style="western"><given-names>C. S.</given-names><surname>Han</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Hancock</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Sharma</surname></string-name>, et&#160;al., &#8220;<article-title>Low Back Pain of Disc, Sacroiliac Joint, or Facet Joint Origin: A Diagnostic Accuracy Systematic Review</article-title>,&#8221; <source>EClinicalMedicine</source><volume>59</volume> (<year>2023</year>): <elocation-id>101960</elocation-id>.<pub-id pub-id-type="pmid">37096189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2023.101960</pub-id><pub-id pub-id-type="pmcid">PMC10121397</pub-id></mixed-citation></ref><ref id="os70150-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="os70150-cit-0004"><string-name name-style="western"><given-names>J.</given-names><surname>Dowdell</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Erwin</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Choma</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Vaccaro</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Iatridis</surname></string-name>, and <string-name name-style="western"><given-names>S. K.</given-names><surname>Cho</surname></string-name>, &#8220;<article-title>Intervertebral Disk Degeneration and Repair</article-title>,&#8221; <source>Neurosurgery</source><volume>80</volume> (<year>2017</year>): <fpage>S46</fpage>&#8211;<lpage>S54</lpage>.<pub-id pub-id-type="pmid">28350945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/neuros/nyw078</pub-id><pub-id pub-id-type="pmcid">PMC5585783</pub-id></mixed-citation></ref><ref id="os70150-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="os70150-cit-0005"><string-name name-style="western"><given-names>S.</given-names><surname>Sharifi</surname></string-name>, <string-name name-style="western"><given-names>S. K.</given-names><surname>Bulstra</surname></string-name>, <string-name name-style="western"><given-names>D. W.</given-names><surname>Grijpma</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Kuijer</surname></string-name>, &#8220;<article-title>Treatment of the Degenerated Intervertebral Disc; Closure, Repair and Regeneration of the Annulus Fibrosus</article-title>,&#8221; <source>Journal of Tissue Engineering and Regenerative Medicine</source><volume>9</volume> (<year>2015</year>): <fpage>1120</fpage>&#8211;<lpage>1132</lpage>.<pub-id pub-id-type="pmid">24616324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/term.1866</pub-id></mixed-citation></ref><ref id="os70150-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="os70150-cit-0006"><string-name name-style="western"><given-names>T.</given-names><surname>Benzakour</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Igoumenou</surname></string-name>, <string-name name-style="western"><given-names>A. F.</given-names><surname>Mavrogenis</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Benzakour</surname></string-name>, &#8220;<article-title>Current Concepts for Lumbar Disc Herniation</article-title>,&#8221; <source>International Orthopaedics</source><volume>43</volume> (<year>2019</year>): <fpage>841</fpage>&#8211;<lpage>851</lpage>.<pub-id pub-id-type="pmid">30506088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00264-018-4247-6</pub-id></mixed-citation></ref><ref id="os70150-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="os70150-cit-0007"><string-name name-style="western"><given-names>S.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Ma</surname></string-name>, and <string-name name-style="western"><given-names>W.</given-names><surname>Ding</surname></string-name>, &#8220;<article-title>Intervertebral Disc Ageing and Degeneration: The Antiapoptotic Effect of Oestrogen</article-title>,&#8221; <source>Ageing Research Reviews</source><volume>57</volume> (<year>2020</year>): <elocation-id>100978</elocation-id>.<pub-id pub-id-type="pmid">31669486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2019.100978</pub-id></mixed-citation></ref><ref id="os70150-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="os70150-cit-0008"><string-name name-style="western"><given-names>V.</given-names><surname>Francisco</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Pino</surname></string-name>, <string-name name-style="western"><given-names>M. &#193;.</given-names><surname>Gonz&#225;lez&#8208;Gay</surname></string-name>, et&#160;al., &#8220;<article-title>A New Immunometabolic Perspective of Intervertebral Disc Degeneration</article-title>,&#8221; <source>Nature Reviews Rheumatology</source><volume>18</volume> (<year>2022</year>): <fpage>47</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">34845360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41584-021-00713-z</pub-id></mixed-citation></ref><ref id="os70150-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="os70150-cit-0009"><string-name name-style="western"><given-names>S.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Fu</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Wu</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Pei</surname></string-name>, &#8220;<article-title>Meniscus, Articular Cartilage and Nucleus Pulposus: A Comparative Review of Cartilage&#8208;Like Tissues in Anatomy, Development and Function</article-title>,&#8221; <source>Cell and Tissue Research</source><volume>370</volume> (<year>2017</year>): <fpage>53</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="pmid">28413859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00441-017-2613-0</pub-id><pub-id pub-id-type="pmcid">PMC5645221</pub-id></mixed-citation></ref><ref id="os70150-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="os70150-cit-0010"><string-name name-style="western"><given-names>X.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Huang</surname></string-name>, et&#160;al., &#8220;<article-title>Injectable Decellularized Nucleus Pulposus&#8208;Based Cell Delivery System for Differentiation of Adipose&#8208;Derived Stem Cells and Nucleus Pulposus Regeneration</article-title>,&#8221; <source>Acta Biomaterialia</source><volume>81</volume> (<year>2018</year>): <fpage>115</fpage>&#8211;<lpage>128</lpage>.<pub-id pub-id-type="pmid">30267879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2018.09.044</pub-id></mixed-citation></ref><ref id="os70150-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="os70150-cit-0011"><string-name name-style="western"><given-names>S.</given-names><surname>Suzuki</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Fujita</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Hosogane</surname></string-name>, et&#160;al., &#8220;<article-title>Excessive Reactive Oxygen Species Are Therapeutic Targets for Intervertebral Disc Degeneration</article-title>,&#8221; <source>Arthritis Research &amp; Therapy</source><volume>17</volume> (<year>2015</year>): <fpage>316</fpage>.<pub-id pub-id-type="pmid">26542776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13075-015-0834-8</pub-id><pub-id pub-id-type="pmcid">PMC4635526</pub-id></mixed-citation></ref><ref id="os70150-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="os70150-cit-0012"><string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Cheng</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhang</surname></string-name>, and <string-name name-style="western"><given-names>X.</given-names><surname>Kang</surname></string-name>, &#8220;<article-title>Oxidative Stress in Intervertebral Disc Degeneration: Molecular Mechanisms, Pathogenesis and Treatment</article-title>,&#8221; <source>Cell Proliferation</source><volume>56</volume> (<year>2023</year>): <elocation-id>e13448</elocation-id>.<pub-id pub-id-type="pmid">36915968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cpr.13448</pub-id><pub-id pub-id-type="pmcid">PMC10472537</pub-id></mixed-citation></ref><ref id="os70150-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="os70150-cit-0013"><string-name name-style="western"><given-names>B.</given-names><surname>Peng</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Hao</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Hou</surname></string-name>, et&#160;al., &#8220;<article-title>Possible Pathogenesis of Painful Intervertebral Disc Degeneration</article-title>,&#8221; <source>Spine</source><volume>31</volume> (<year>2006</year>): <fpage>560</fpage>&#8211;<lpage>566</lpage>.<pub-id pub-id-type="pmid">16508552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.brs.0000201324.45537.46</pub-id></mixed-citation></ref><ref id="os70150-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="os70150-cit-0014"><string-name name-style="western"><given-names>Y.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Chai</surname></string-name>, and <string-name name-style="western"><given-names>X.</given-names><surname>Wu</surname></string-name>, &#8220;<article-title>Targeting Ferroptosis to Enhance the Efficacy of Mesenchymal Stem Cell&#8208;Based Treatments for Intervertebral Disc Degeneration</article-title>,&#8221; <source>International Journal of Biological Sciences</source><volume>21</volume> (<year>2025</year>): <fpage>1222</fpage>&#8211;<lpage>1241</lpage>.<pub-id pub-id-type="pmid">39897051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijbs.107021</pub-id><pub-id pub-id-type="pmcid">PMC11781166</pub-id></mixed-citation></ref><ref id="os70150-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="os70150-cit-0015"><string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Tan</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Zhang</surname></string-name>, et&#160;al., &#8220;<article-title>Injectable Dynamic Hydrogel With Responsive Mechanical Reinforcing Ability Reverses Intervertebral Disc Degeneration by Suppressing Ferroptosis and Restoring Matrix Homeostasis</article-title>,&#8221; <source>Advanced Functional Materials</source><volume>34</volume> (<year>2024</year>): <elocation-id>2310416</elocation-id>.</mixed-citation></ref><ref id="os70150-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="os70150-cit-0016"><string-name name-style="western"><given-names>Y.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wan</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Jiang</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zhang</surname></string-name>, and <string-name name-style="western"><given-names>W.</given-names><surname>Cheng</surname></string-name>, &#8220;<article-title>GPX4: The Hub of Lipid Oxidation, Ferroptosis, Disease and Treatment</article-title>,&#8221; <source>Biochimica et Biophysica Acta &#8208; Reviews on Cancer</source><volume>1878</volume> (<year>2023</year>): <elocation-id>188890</elocation-id>.<pub-id pub-id-type="pmid">37001616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbcan.2023.188890</pub-id></mixed-citation></ref><ref id="os70150-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="os70150-cit-0017"><string-name name-style="western"><given-names>B.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Palmitoylation&#8208;Dependent Regulation of GPX4 Suppresses Ferroptosis</article-title>,&#8221; <source>Nature Communications</source><volume>16</volume> (<year>2025</year>): <fpage>867</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-025-56344-5</pub-id><pub-id pub-id-type="pmcid">PMC11746948</pub-id><pub-id pub-id-type="pmid">39833225</pub-id></mixed-citation></ref><ref id="os70150-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="os70150-cit-0018"><string-name name-style="western"><given-names>W.</given-names><surname>Fan</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Fan</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Rare Ginsenosides: A Unique Perspective of Ginseng Research</article-title>,&#8221; <source>Journal of Advanced Research</source><volume>66</volume> (<year>2024</year>): <fpage>303</fpage>&#8211;<lpage>328</lpage>.<pub-id pub-id-type="pmid">38195040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jare.2024.01.003</pub-id><pub-id pub-id-type="pmcid">PMC11674801</pub-id></mixed-citation></ref><ref id="os70150-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="os70150-cit-0019"><string-name name-style="western"><given-names>S.</given-names><surname>Kang</surname></string-name>, <string-name name-style="western"><given-names>S.&#8208;J.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>A.&#8208;Y.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>H.&#8208;Y.</given-names><surname>Chung</surname></string-name>, and <string-name name-style="western"><given-names>D.&#8208;S.</given-names><surname>Im</surname></string-name>, &#8220;<article-title>Ginsenoside Rg3 Promotes Inflammation Resolution Through M2 Macrophage Polarization</article-title>,&#8221; <source>Journal of Ginseng Research</source><volume>42</volume> (<year>2018</year>): <fpage>68</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">29348724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jgr.2016.12.012</pub-id><pub-id pub-id-type="pmcid">PMC5766702</pub-id></mixed-citation></ref><ref id="os70150-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="os70150-cit-0020"><string-name name-style="western"><given-names>Y.</given-names><surname>Shan</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Zhu</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Kong</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Ying</surname></string-name>, and <string-name name-style="western"><given-names>W.</given-names><surname>Zhu</surname></string-name>, &#8220;<article-title>Ginsenoside Rg3 Ameliorates Acute Pancreatitis by Activating the NRF2/HO&#8208;1&#8208;Mediated Ferroptosis Pathway</article-title>,&#8221; <source>International Journal of Molecular Medicine</source><volume>50</volume> (<year>2022</year>): <elocation-id>89</elocation-id>.<pub-id pub-id-type="pmid">35582998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2022.5144</pub-id><pub-id pub-id-type="pmcid">PMC9162051</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="retraction-forward" ext-link-type="pmc" xlink:href="PMC11554378"/></mixed-citation></ref><ref id="os70150-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="os70150-cit-0021"><string-name name-style="western"><given-names>X.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Wu</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Zhu</surname></string-name>, &#8220;<article-title>Ginsenoside Rg3 Attenuates Ovariectomy&#8208;Induced Osteoporosis via AMPK/mTOR Signaling Pathway</article-title>,&#8221; <source>Drug Development Research</source><volume>81</volume> (<year>2020</year>): <fpage>875</fpage>&#8211;<lpage>884</lpage>.<pub-id pub-id-type="pmid">32898934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ddr.21705</pub-id></mixed-citation></ref><ref id="os70150-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="os70150-cit-0022"><string-name name-style="western"><given-names>L.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Guo</surname></string-name>, et&#160;al., &#8220;<article-title>Ginsenoside Rg3&#8208;Loaded, Reactive Oxygen Species&#8208;Responsive Polymeric Nanoparticles for Alleviating Myocardial Ischemia&#8208;Reperfusion Injury</article-title>,&#8221; <source>Journal of Controlled Release</source><volume>317</volume> (<year>2020</year>): <fpage>259</fpage>&#8211;<lpage>272</lpage>.<pub-id pub-id-type="pmid">31783047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2019.11.032</pub-id><pub-id pub-id-type="pmcid">PMC7384207</pub-id></mixed-citation></ref><ref id="os70150-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="os70150-cit-0023"><string-name name-style="western"><given-names>W.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>S.&#8208;X.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Ai</surname></string-name>, et&#160;al., &#8220;<article-title>Ginsenoside Rg3 Promotes Cell Growth Through Activation of mTORC1</article-title>,&#8221; <source>Frontiers in Cell and Development Biology</source><volume>9</volume> (<year>2021</year>): <elocation-id>730309</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcell.2021.730309</pub-id><pub-id pub-id-type="pmcid">PMC8473834</pub-id><pub-id pub-id-type="pmid">34589493</pub-id></mixed-citation></ref><ref id="os70150-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="os70150-cit-0024"><string-name name-style="western"><given-names>J.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Wu</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Xu</surname></string-name>, &#8220;<article-title>Ginsenoside Rg3 Exhibits Anti&#8208;Catabolic and Anti&#8208;Apoptotic Effects in IL&#8208;1&#946; Treatedhuman Disc Nucleus Pulposus Cells and in a Rat Model of Disc Degeneration Byinactivating the MAPK Pathway</article-title>,&#8221; <source>Cellular and Molecular Biology (Noisy&#8208;le&#8208;Grand, France)</source><volume>70</volume> (<year>2024</year>): <fpage>233</fpage>&#8211;<lpage>238</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.14715/cmb/2024.70.1.32</pub-id><pub-id pub-id-type="pmid">38372089</pub-id></mixed-citation></ref><ref id="os70150-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="os70150-cit-0025"><string-name name-style="western"><given-names>W.&#8208;C.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>T.&#8208;H.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>K.&#8208;W.</given-names><surname>Yeh</surname></string-name>, <string-name name-style="western"><given-names>Y.&#8208;L.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>S.&#8208;C.</given-names><surname>Shen</surname></string-name>, and <string-name name-style="western"><given-names>C.&#8208;J.</given-names><surname>Liou</surname></string-name>, &#8220;<article-title>Ginsenoside Rg3 Ameliorates Allergic Airway Inflammation and Oxidative Stress in Mice</article-title>,&#8221; <source>Journal of Ginseng Research</source><volume>45</volume> (<year>2021</year>): <fpage>654</fpage>&#8211;<lpage>664</lpage>.<pub-id pub-id-type="pmid">34764720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jgr.2021.03.002</pub-id><pub-id pub-id-type="pmcid">PMC8569325</pub-id></mixed-citation></ref><ref id="os70150-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="os70150-cit-0026"><string-name name-style="western"><given-names>X.</given-names><surname>Zhao</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Xu</surname></string-name>, et&#160;al., &#8220;<article-title>Degenerated Nucleus Pulposus Cells Derived Exosome Carrying miR&#8208;27a&#8208;3p Aggravates Intervertebral Disc Degeneration by Inducing M1 Polarization of Macrophages</article-title>,&#8221; <source>Journal of Nanobiotechnology</source><volume>21</volume> (<year>2023</year>): <fpage>317</fpage>.<pub-id pub-id-type="pmid">37667246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-023-02075-y</pub-id><pub-id pub-id-type="pmcid">PMC10478255</pub-id></mixed-citation></ref><ref id="os70150-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="os70150-cit-0027"><string-name name-style="western"><given-names>H.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Jiang</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Pang</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Zhou</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Gu</surname></string-name>, &#8220;<article-title>Acacetin Alleviates Inflammation and Matrix Degradation in Nucleus Pulposus Cells and Ameliorates Intervertebral Disc Degeneration In&#160;Vivo</article-title>,&#8221; <source>Drug Design, Development and Therapy</source><volume>14</volume> (<year>2020</year>): <fpage>4801</fpage>&#8211;<lpage>4813</lpage>.<pub-id pub-id-type="pmid">33204066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S274812</pub-id><pub-id pub-id-type="pmcid">PMC7667005</pub-id></mixed-citation></ref><ref id="os70150-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="os70150-cit-0028"><string-name name-style="western"><given-names>W.&#8208;H.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>H.&#8208;Y.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>W.&#8208;C.</given-names><surname>Lo</surname></string-name>, et&#160;al., &#8220;<article-title>Intervertebral Disc Regeneration in an <italic toggle="yes">Ex Vivo</italic> Culture System Using Mesenchymal Stem Cells and Platelet&#8208;Rich Plasma</article-title>,&#8221; <source>Biomaterials</source><volume>30</volume> (<year>2009</year>): <fpage>5523</fpage>&#8211;<lpage>5533</lpage>.<pub-id pub-id-type="pmid">19646749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2009.07.019</pub-id></mixed-citation></ref><ref id="os70150-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="os70150-cit-0029"><string-name name-style="western"><given-names>K.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Kang</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Yan</surname></string-name>, et&#160;al., &#8220;<article-title>Rescuing ACE2&#8208;Deficiency&#8208;Mediated Nucleus Pulposus Senescence and Intervertebral Disc Degeneration by a Nanotopology&#8208;Enhanced RNAi System</article-title>,&#8221; <source>Advanced Science</source><volume>12</volume>, no. <issue>9</issue> (<year>2025</year>): <elocation-id>e2412908</elocation-id>.<pub-id pub-id-type="pmid">39804951</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202412908</pub-id><pub-id pub-id-type="pmcid">PMC11884558</pub-id></mixed-citation></ref><ref id="os70150-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="os70150-cit-0030"><string-name name-style="western"><given-names>X.</given-names><surname>Yang</surname></string-name> and <string-name name-style="western"><given-names>X.</given-names><surname>Li</surname></string-name>, &#8220;<article-title>Nucleus Pulposus Tissue Engineering: A Brief Review</article-title>,&#8221; <source>European Spine Journal</source><volume>18</volume> (<year>2009</year>): <fpage>1564</fpage>&#8211;<lpage>1572</lpage>.<pub-id pub-id-type="pmid">19603198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00586-009-1092-8</pub-id><pub-id pub-id-type="pmcid">PMC2899402</pub-id></mixed-citation></ref><ref id="os70150-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="os70150-cit-0031"><string-name name-style="western"><given-names>C.</given-names><surname>Feng</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Lan</surname></string-name>, et&#160;al., &#8220;<article-title>ROS: Crucial Intermediators in the Pathogenesis of Intervertebral Disc Degeneration</article-title>,&#8221; <source>Oxidative Medicine and Cellular Longevity</source><volume>2017</volume> (<year>2017</year>): <elocation-id>5601593</elocation-id>.<pub-id pub-id-type="pmid">28392887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2017/5601593</pub-id><pub-id pub-id-type="pmcid">PMC5368368</pub-id></mixed-citation></ref><ref id="os70150-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="os70150-cit-0032"><string-name name-style="western"><given-names>J.</given-names><surname>Bai</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Fan</surname></string-name>, et&#160;al., &#8220;<article-title>Reactive Oxygen Species&#8208;Scavenging Scaffold With Rapamycin for Treatment of Intervertebral Disk Degeneration</article-title>,&#8221; <source>Advanced Healthcare Materials</source><volume>9</volume> (<year>2020</year>): <elocation-id>1901186</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.201901186</pub-id><pub-id pub-id-type="pmid">31820852</pub-id></mixed-citation></ref><ref id="os70150-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="os70150-cit-0033"><string-name name-style="western"><given-names>Y.</given-names><surname>Dou</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zhao</surname></string-name>, and <string-name name-style="western"><given-names>Q.</given-names><surname>Yang</surname></string-name>, &#8220;<article-title>Intervertebral Disk Degeneration: The Microenvironment and Tissue Engineering Strategies</article-title>,&#8221; <source>Frontiers in Bioengineering and Biotechnology</source><volume>9</volume> (<year>2021</year>): <elocation-id>118</elocation-id>, <pub-id pub-id-type="doi">10.3389/fbioe.2021.592118</pub-id>.<pub-id pub-id-type="pmcid">PMC8329559</pub-id><pub-id pub-id-type="pmid">34354983</pub-id></mixed-citation></ref><ref id="os70150-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="os70150-cit-0034"><string-name name-style="western"><given-names>L.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>He</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Cartilage Intermediate Layer Protein Affects the Progression of Intervertebral Disc Degeneration by Regulating the Extracellular Microenvironment (Review)</article-title>,&#8221; <source>International Journal of Molecular Medicine</source><volume>47</volume> (<year>2021</year>): <fpage>475</fpage>&#8211;<lpage>484</lpage>.<pub-id pub-id-type="pmid">33416131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2020.4832</pub-id><pub-id pub-id-type="pmcid">PMC7797476</pub-id></mixed-citation></ref><ref id="os70150-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="os70150-cit-0035"><string-name name-style="western"><given-names>Y.</given-names><surname>Xie</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Kang</surname></string-name>, <string-name name-style="western"><given-names>D. J.</given-names><surname>Klionsky</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Tang</surname></string-name>, &#8220;<article-title>GPX4 in Cell Death, Autophagy, and Disease</article-title>,&#8221; <source>Autophagy</source><volume>19</volume> (<year>2023</year>): <fpage>2621</fpage>&#8211;<lpage>2638</lpage>.<pub-id pub-id-type="pmid">37272058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2023.2218764</pub-id><pub-id pub-id-type="pmcid">PMC10472888</pub-id></mixed-citation></ref><ref id="os70150-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="os70150-cit-0036"><string-name name-style="western"><given-names>S.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>E.&#8208;J.</given-names><surname>Kwon</surname></string-name>, et&#160;al., &#8220;<article-title>The Protective Role of GPX4 in Na&#239;ve ESCs Is Highlighted by Induced Ferroptosis Resistance Through GPX4 Expression</article-title>,&#8221; <source>Redox Biology</source><volume>81</volume> (<year>2025</year>): <elocation-id>103539</elocation-id>.<pub-id pub-id-type="pmid">40010136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.redox.2025.103539</pub-id><pub-id pub-id-type="pmcid">PMC11908625</pub-id></mixed-citation></ref><ref id="os70150-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="os70150-cit-0037"><string-name name-style="western"><given-names>Q.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Zhang</surname></string-name>, et&#160;al., &#8220;<article-title>
<italic toggle="yes">In Vitro</italic> and <italic toggle="yes">In Silico</italic> Evaluation of Stereoselective Effect of Ginsenoside Isomers on Platelet P2Y12 Receptor</article-title>,&#8221; <source>Phytomedicine</source><volume>64</volume> (<year>2019</year>): <elocation-id>152899</elocation-id>.<pub-id pub-id-type="pmid">31454649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phymed.2019.152899</pub-id></mixed-citation></ref><ref id="os70150-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="os70150-cit-0038"><string-name name-style="western"><given-names>X.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Tsauo</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Geng</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Zhao</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Lei</surname></string-name>, and <string-name name-style="western"><given-names>X.</given-names><surname>Li</surname></string-name>, &#8220;<article-title>Ginsenoside Rg3 Decreases NHE1 Expression via Inhibiting EGF&#8208;EGFR&#8208;ERK1/2&#8208;HIF&#8208;1&#945; Pathway in Hepatocellular Carcinoma: A Novel Antitumor Mechanism</article-title>,&#8221; <source>American Journal of Chinese Medicine</source><volume>46</volume> (<year>2018</year>): <fpage>1915</fpage>&#8211;<lpage>1931</lpage>.<pub-id pub-id-type="pmid">30525897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1142/S0192415X18500969</pub-id></mixed-citation></ref><ref id="os70150-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="os70150-cit-0039"><string-name name-style="western"><given-names>Y.</given-names><surname>Gao</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Yan</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, et&#160;al., &#8220;<article-title>Ginsenoside Rg3 Ameliorates Acetaminophen&#8208;Induced Hepatotoxicity by Suppressing Inflammation and Oxidative Stress</article-title>,&#8221; <source>Journal of Pharmacy and Pharmacology</source><volume>73</volume> (<year>2021</year>): <fpage>322</fpage>&#8211;<lpage>331</lpage>.<pub-id pub-id-type="pmid">33793882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jpp/rgaa069</pub-id></mixed-citation></ref><ref id="os70150-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="os70150-cit-0040"><string-name name-style="western"><given-names>X.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Yuan</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Jiang</surname></string-name>, &#8220;<article-title>Molecular Mechanism of Ginsenoside Rg3 Alleviation in Osteoporosis via Modulation of KPNA2 and the NF&#8208;&#954;B Signalling Pathway</article-title>,&#8221; <source>Clinical and Experimental Pharmacology and Physiology</source><volume>52</volume> (<year>2025</year>): <elocation-id>e70019</elocation-id>.<pub-id pub-id-type="pmid">39821958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1440-1681.70019</pub-id></mixed-citation></ref></ref-list></back></article>